Thromboembolic prophylaxis in moderate-risk patients undergoing elective abdominal surgery: Decision and cost-effectiveness analyses

Pharmacotherapy

Volumn 16, Issue 6 I, 1996, Pages 1111-1127

  Mamdani, Muhammad M ^a,b   Weingarten, Cindy M ^b   Stevenson, James G ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DALTEPARIN; DEXTRAN; FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; WARFARIN;

ABDOMINAL SURGERY; ARTICLE; BLEEDING; CLINICAL TRIAL; COMPRESSION THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DEEP VEIN THROMBOSIS; DRUG COST; ELECTIVE SURGERY; EMBOLECTOMY; EMBOLISM PREVENTION; HIGH RISK PATIENT; HUMAN; LUNG EMBOLISM; MORTALITY; RETROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; DALTEPARIN; GRAVITY SUITS; HEPARIN; HUMANS; LAPAROTOMY; MODELS, ECONOMIC; POSTOPERATIVE COMPLICATIONS; THROMBOEMBOLISM; UNITED STATES;

EID: 0029803634     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Salzman EW, Davies GC. Prophylaxis of venous thromboembolism: analysis of cost-effectiveness. Ann Surg 1980;191(2):207-18.
2. Carter C, Gent C, Leclerc JR. The epidemiology of venous thrombosis. In: Coleman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice, 2nd ed. Philadelphia: JB Lippincott, 1987:1185-98.
3. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin - overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;318(18):1162-73.
4. Kakkar VV, Corrigan TP, Fossard DP, et al. Prevention of fatal postoperative pulmonary embolism by low doses of heparin: an international multicentre trial. Lancet 1975;2:45-51.
5. Kakkar VV, Flanc C, Howe CT, Clarke MB. Natural history of postoperative deep-vein thrombosis. Lancet 1969;2:230-2.
6. Kiil J, Kiil J, Axelson F, Andersen D. Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin. Lancet 1978;1:1115-16.
7. Hull RD, Hirsh J, Sackett DL, Stoddard GL. Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients. Can Med Assoc J 1982;127:990-5.
8. Dalen JE, Alpert JS. Natural history of pulmonary embolism. In: Sasahara AA, Sonnenblick EH, Lesch M, eds. Pulmonary emboli. New York: Grune & Stratton, 1974:77-88.
9. Pachter HL, Riles TS. Low dose heparin: bleeding and wound complications in the surgical patient: a prospective randomized study. Ann Surg 1977;186(6):669-74.
10. Bergqvist D, Matzsch T. Cost/benefit aspects on thromboprophylaxis. Haemostasis 1993;23(S1):15-19.
11. Bergqvist D, Jendteg S. The economics of general thromboembolic prophylaxis. World J Surg 1988;12:349-55.
12. Clagett GP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995;108(4):312S-34.
13. Caprini JA, Acelus JI, Hoffman K. Prevention of venous thromboembolism in North America: results of a survey among general surgeons. J Vasc Surg 1994;20(5):751-8.
14. Caprini JA, Arcelius JI, Traverse CI, Hasty JH. Low molecular weight heparins and external pneumatic compression as options for venous thromboembolism prophylaxis: a surgeon's perspective. Sem Thromb Haemost 1991;17(4):356-66.
15. Comerota AJ, Katz ML, White JV. Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail? Am J Surg 1992;164:265-8.
16. Nurmohamed MT, Rosendal FR, Buller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:1526.
17. Johnson EA, Kirkwood TBL, Infram GI, et al. Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb Haemost 1976;35(3):586-91.
18. Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing AW. Low molecular weight heparin: a critical analysis of clinical trials Pharm Rev 1994;46(1):89-109.
19. Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparins and heparin. Blood 1982;59(6):1239-45.
20. Hartl P, Brucke P, Dienstl E, Vinazzer H. Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and fragmin. Thromb Res 1990;57:577-84.
21. Kakkar VV, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993;341:259-65.
22. Bounameaux H, Huber H, Khabiri E, Schneider PA, Didier D, Rohner A. Unexpectedly high rate of phlebographic deep venous thrombosis after elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin. Arch Surg 1993;128:326-8.
23. Pharmacia, Inc. Fragmin (dalteparin) package insert. Columbus, OH; 1995.
24. Richardson WS, Detsky AS. User's guide to the medical literature: how to use a clinical decision analysis. A. Are the results of the study valid? JAMA 1995;273(16):1292-5.
25. Lorenz EW, Jones MK. St. Anthony's DRG guidebook 1995. Reston, VA: St. Anthony Publishing, Inc., 1994.
26. Mol WEM, Egberts TCG. Prophylaxis for venous thromboembolism in hip fracture surgery: total costs and cost-effectiveness in The Netherlands. PharmacoEconomics 1994;5(1):48-55.
27. Heaton D, Pearce M. Low molecular weight versus unfractionated heparin: a clinical and economic appraisal. PharmacoEconomics 1995;8(2):91-9.
28. Anderson DR, O'Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low molecular weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993;119(11):1105-12.
29. Oster G, Tuden RL, Colidtz GA, et al. Prevention of venous thromboembolism after general surgery: cost-effectiveness analysis of alternative approaches to prophylaxis. Am J Med 1987;82:889-99.
30. Sackett DL, Haynes RB, Tugwell P. Clinical epidemiology: a basic science for clinical medicine. Boston: Little, Brown, 1985.
31. Bergqvist D, Burmark US, Frisell J, et al. Prospective double-blind comparison between fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications. Haemostasis 1986;16(S2):11-18.
32. Caen JP. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery: a French multicenter trial. Thrombos Haemost 1988;59(2): 216-20.
33. Gillum RF. Pulmonary embolism and thrombophlebitis in the United States, 1970-1985. Am Heart J 1987;114:1262-4.
34. Samkoff JS, Comstock GW. Epidemiology of pulmonary embolism: mortality in a general population. Am J Epidemiol 1981;114:488-95.
35. Pineo GF, Brain MC, Gallus AS, Hirsh J, Hatton MW, Regoeczi E. Tumors, mucus production, and hypercoagulability. Ann NY Acad Sci 1974;230:262-70.
36. Kakkar VV, Howe CT, Nicolaides AN, Renney JT, Clarke MB. Deep vein thrombosis of the leg: is there a "high risk" group? Am J Surg 1970;120(4):527-30.
37. Coon WW, Willis W. Recurrence of venous thromboembolism. Surgery 1973;73:823-7.
38. Nicolaides AN, Kakkar VV, Renney JT, Kidner PH, Hutchison DC, Clarke MB. Myocardial infarction and deep vein thrombosis. Br Med J 1971;1:432-4.
39. Cheng KK, Lai ST, Yu TJ, et al. Post-operative deep vein thrombosis in the Taiwanese Chinese population. Am J Surg 1987;153:302-5.
40. Cunningham IGE, Yong NK. The incidence of postoperative deep vein thrombosis in Malaysia. Br J Surg 1974;61:482-3.
41. 125I-labeled fibrinogen. Br Med J 1978;2:1607.
42. Warlow C, Ogston D, Douglas AS. Venous thrombosis after strokes. Lancet 1972;1:1305-6.
43. Valla D, Le MG, Poynard T, Zucman N, Rueff B, Benhamou JP. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives - a case control study. Gastroenterology 1986;90(4):807-11.
44. Gladson CL, Sharrel I, Hach V, Beck KH, Griffin JH. The frequency of type I heterozygous protein S deficiency and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1987;59(1):18-22.
45. Scurr JH, Coleridge-Smith PD, Hasty JH. Regimen for improved effectiveness of intermittent pneumatic compression in deep vein thrombosis prophylaxis. Surgery 1987;102(5): 816-20.
46. Nicolaides AN, Fernandes JF, Pollock AV. Intermittent sequential pneumatic compression of the legs in the prevention of venous stasis and postoperative deep venous thrombosis. Surgery 1980;87(1):69-76.
47. Coe NP, Collins REC, Klein LA, et al. Prevention of deep vein thrombosis in urological patients: a controlled, randomized trial of low-dose heparin and external pneumatic compression boots. Surgery 1978;83(2):230-4.
48. Muhe E. Intermittent sequential high-pressure compression of the leg: a new method of preventing deep vein thrombosis. Am J Surg 1984;147:781-5.
49. Sabri S, Roberts VC, Cotton LT. Prevention of early postoperative deep vein thrombosis by intermittent compression of the leg during surgery. Br Med J 1971;4:394-6.
50. Rose SC, Zwiebel WJ, Miller FJ. Distribution of acute lower extremity deep vein thrombosis in symptomatic and asymptomatic patients: imaging implications. J Ultrasound Med 1994;13(4):243-50.
51. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med 1992;326(19):1240-5.
52. Witty LA, Krichman A, Tapson VF. Thrombolytic therapy for venous thromboembolism: utilization by practicing pulmonologists. Arch Intern Med 1994;154:1601-4.
53. Stein PD, Hull RD, Raskob G. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism: consideration of noninvasive management. Ann Intern Med 1994;121(5):313-17.
54. Gallus AS, Hirsh J, O'Brien SE, McBride JA, Tuttle RJ, Gent M. Prevention of venous thrombosis with small, subcutaneous doses of heparin. JAMA 1976;235(18):1980-2.
55. Gruber UF, Duckert F, Fridrich R, Torhorst J, Rem J. Prevention of postoperative thromboembolism by dextran 40, low doses of heparin, or xantinol nicotinate. Lancet 1977;1:207-10.
56. Gordon-Smith IC, Grundy DJ, LeQuesne LP, Newcombe JF, Bramble FJ. Controlled trial of two regimens of subcutaneous heparin in the prevention of postoperative deep vein thrombosis. Lancet 1972;1:1133-5.
57. Sagar S, Massey J, Sanderson JM. Low-dose heparin prophylaxis against fatal pulmonary embolism. Br Med J 1975;4:257-9.
58. Joffe SN. The incidence of postoperative deep vein thrombosis. Thromb Res 1975;7:141-8.
59. Hartsuck JM, Greenfield LJ. Postoperative thromboembolism: a clinical study with 1251 fibrinogen and pulmonary scanning. Ann Surg 1973;107:733-9.
60. Anderson FA, Wheeler HB. Venous thromboembolism: risk factors and prophylaxis. Clin Chest Med 1995;16(2):235-51.
61. Moser KM. Venous thromboembolism. Am Rev Respir Dis 1990;141:235-49.
62. Agnelli G. Aniticoagulation in the prevention and treatment of pulmonary embolism. Chest 1995;107(1):39S-44.
63. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;332:1260-4.
64. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1995;108(4):335S-51.
65. Wittkowsky AK. Thrombosis. In: Koda-Kimble MA, Young LY, eds. Applied therapeutics: the clinical use of drugs. Vancouver: Applied Therapeutics, 1995:12.1-12.25.
66. Goldhaber SZ. Venous thromboembolism: prevention, treatment, and relationship to paradoxical embolization. Cardiol Clin. 1994;12(3):505-16.
67. Hirsh J, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1992;102(4):337S-51.
68. Matzdorff AC, Green D. Deep vein thrombosis and pulmonary embolism: prevention, diagnosis, and treatment. Geriatrics 1992;47(8):48-63.
69. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975;17:259-70.
70. Bell WR, Simon TL. Current status of pulmonary thromboembolic disease: pathophysiology, diagnosis, prevention, and treatment. Am Heart J 1982;103:239-62.
71. Bell W, Blackmon JR, deGroot W, et al. Urokinase streptokinase pulmonary embolism trial: phase II results. JAMA 1974;229:1606-13.
72. Meyer G, Tamisier D, Sors H, et al. Pulmonary embolectomy: a 20-year experience at one center. Ann Thorac Surg 1991;51:232-6.
73. Leclerc J. Venous thromboembolic disorders. Philadelphia: Lea & Febiger, 1991.
74. Gulba DC, Schmid C. Medical compared with surgical treatment for massive pulmonary embolism. Lancet 1994;343:576-7.
75. Stewart JR, Greenfield LJ. Transvenous vena caval filtration and pulmonary embolectomy. Surg Clin 1982;62(3):411-30.
76. Greenfield LJ, Michna BA. Twelve year clinical experience with the Greenfield vena cava filter. Surgery 1988;104:706-12.
77. Becker DM, Philbrick JT, Selby JB. Inferior vena cava filters: indications, safety, effectiveness. Arch Intern Med 1992; 152:1985-94.
78. Levine MN, Hirsh J, Landefeld S, Raskob G. Hemorrhagic complications of anticoagulant treatment. Chest 1992; 102(S4):408S-25.
79. Goldhaber SZ. Evolving concepts in thrombolytic therapy for pulmonary embolism. Chest 1992;101S:183S-5.
80. Molina JE, Hunter DW, Yedlicka JW, Cerra FB. Thrombolytic therapy for postoperative pulmonary embolism. Am J Surg 1992;163:375-80.
81. Drummond MF, Stoddard GL, Torrance GW. Methods for the economic evaluation of health care programmes. New York: Oxford University Press, 1994.
82. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296:716-21.
83. Jansen H. Dextran as prophylaxis against thromboembolism in general surgery. Acta Chir Scand 1968;387S:86-7.
84. Hull RD, Raskob GE, Hirsh J. Prophylaxis of venous thromboembolism: an overview. Chest 1986;89S(5):374S-83.
85. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
86. Hull RD, Raskob GE, Gent M, et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA 1990;263(17):2313-17.
87. Curry N, Bardana EJ, Pirofsky B. Heparin sensitivity: report of a case. Arch Intern Med 1973;132(5):744-5.
88. Browse NL, Hall JH. Effect of dipyridamole on the incidence of clinically detectable deep vein thrombosis. Lancet 1969;2: 718-21.
89. Butterfield WJH, Hicks BH, Ambler AR, et al. Effect of aspirin on postoperative venous thrombosis. Lancet 1972;2:441-4.
90. Stadil F. Macrodex prophylaxis in postoperative thrombosis. Acta Chir Scand 1968;387S:88-90.
91. Carter AE, Eban R, Perrett RD. Prevention of postoperative deep vein thrombosis and pulmonary embolism. Br Med J 1971;1:312-14.
92. Joffe SN. Drug prevention of postoperative deep vein thrombosis: a comparative study of calcium heparinate and sodium pentosan polysulfate. Arch Surg 1976;111:37-40
93. Caprini JA, Scurr JH, Hasty JH. Role of compression modalities in a prophylactic program for deep vein thromboses. Semin Thromb Hemost 1988;14S:77-87.
94. Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo-controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost 1989;62(4):1046-9.